Shows
Soul Pitt Media Health & Business Report with Craig Dawson#87 | Interview with Alexander B. Olawaiye, MD | Professor / Department of Obstetrics / Gynecology and Reproductive Sciences at UPMCSoul Pitt Media Health & Business Report Episode #87 | Interview with Alexander B. Olawaiye, MD | Professor / Department of Obstetrics / Gynecology and Reproductive Sciences at UPMC
Join Craig as he discusses with Dr. Olawaiye:
1) Dr. Olawaiye, growing up in Nigeria, did you always dream of being a physician?
2) After you completed medical school in London, what made you want to come to the United States?
3) Dr. Olawaiye, what advice can you give our younger listeners who may want to pursue a medical career?
Additionally, make sure...2024-11-1336 min
Listen to Gynecologic Oncology2023 FIGO staging for endometrial cancer: a reappraisal on the path to continuous improvementReviews: 2023 changes to FIGO endometrial cancer staging: Counterpoint; 2023 FIGO staging system for endometrial cancer: The evolution of the revolution
Editorial: 2023 FIGO staging for endometrial cancer, a look at both sides of the coin
Hosted by: Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic Oncology
Featuring: Dr. Alexander Olawaiye, MD, University of Pittsburgh School of Medicine, USA
Dr. David Gaffney, MD-PhD, University of Utah, USA
Dr. Mario Leitao, Jr., MD, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, USA2024-07-0837 min
Treating TogetherAdvancing the Treatment of Cervical and Endometrial CancersIn season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.2021-06-1533 min
Engaging Experts by Journal of Clinical PathwaysImportance of the PRIMA Study in the Context of Ovarian Cancer TreatmentAlexander Olawaiye, MD, associate professor of gynecologic oncology, University of Pittsburgh, and Magee-Womens Hospital, University of Pittsburgh Medical Center, contextualizes the results of the PRIMA study and the support for PARP inhibitors in the maintenance and upfront treatment settings of ovarian cancer regardless of germline mutation.2020-01-2715 min